TY - JOUR
T1 - Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe
AU - Veronesi, Giulia
AU - Baldwin, David R
AU - Henschke, Claudia I
AU - Ghislandi, Simone
AU - Iavicoli, Sergio
AU - Oudkerk, Matthijs
AU - De Koning, Harry J
AU - Shemesh, Joseph
AU - Field, John K
AU - Zulueta, Javier J
AU - Horgan, Denis
AU - Fiestas Navarrete, Lucia
AU - Valentino Infante, Maurizio
AU - Novellis, Pierluigi
AU - Murray, Rachael L
AU - Peled, Nir
AU - Rampinelli, Cristiano
AU - Rocco, Gaetano
AU - Rzyman, Witold
AU - Scagliotti, Giorgio Vittorio
AU - Tammemagi, Martin C
AU - Bertolaccini, Luca
AU - Triphuridet, Natthaya
AU - Yip, Rowena
AU - Rossi, Alexia
AU - Senan, Suresh
AU - Ferrante, Giuseppe
AU - Brain, Kate
AU - van der Aalst, Carlijn
AU - Bonomo, Lorenzo
AU - Consonni, Dario
AU - Van Meerbeeck, Jan P
AU - Maisonneuve, Patrick
AU - Novello, Silvia
AU - Devaraj, Anand
AU - Saghir, Zaigham
AU - Pelosi, Giuseppe
PY - 2020/6/24
Y1 - 2020/6/24
N2 - Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39-61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the "Initiative for European Lung Screening (IELS)"-a large international group of physicians and other experts concerned with lung cancer-agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.
AB - Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39-61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the "Initiative for European Lung Screening (IELS)"-a large international group of physicians and other experts concerned with lung cancer-agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.
U2 - 10.3390/cancers12061672
DO - 10.3390/cancers12061672
M3 - Review article
C2 - 32599792
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 6
ER -